Charles Schwab
EGRX

Charles Schwab’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Charles Schwab’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,589
Closed -$283K – 3622
2024
Q2 		$283K Sell
50,589
-23,338
-32% -$102K ﹤0.01% 3381
2024
Q1 		$387K Buy
73,927
+1,645
+2% +$9.03K ﹤0.01% 3118
2023
Q4 		$378K Sell
72,282
-38,072
-34% -$376K ﹤0.01% 3175
2023
Q3 		$1.74M Buy
110,354
+3,679
+3% +$66.1K ﹤0.01% 2641
2023
Q2 		$2.07M Sell
106,675
-1,454
-1% -$34.5K ﹤0.01% 2538
2023
Q1 		$3.07M Sell
108,129
-54,802
-34% -$1.63M ﹤0.01% 2403
2022
Q4 		$4.76M Buy
162,931
+19,807
+14% +$630K ﹤0.01% 2236
2022
Q3 		$3.78M Buy
143,124
+20,630
+17% +$757K ﹤0.01% 2367
2022
Q2 		$5.44M Buy
122,494
+11,930
+11% +$548K ﹤0.01% 2151
2022
Q1 		$5.47M Buy
110,564
+13,422
+14% +$644K ﹤0.01% 2235
2021
Q4 		$4.95M Buy
97,142
+15,999
+20% +$829K ﹤0.01% 2361
2021
Q3 		$4.53M Buy
81,143
+487
+0.6% +$24K ﹤0.01% 2426
2021
Q2 		$3.45M Buy
80,656
+3,653
+5% +$151K ﹤0.01% 2529
2021
Q1 		$3.21M Buy
77,003
+1,809
+2% +$84K ﹤0.01% 2508
2020
Q4 		$3.5M Sell
75,194
-1,299
-2% -$60.8K ﹤0.01% 2387
2020
Q3 		$3.25M Buy
76,493
+8,299
+12% +$363K ﹤0.01% 2292
2020
Q2 		$3.27M Buy
68,194
+8,047
+13% +$401K ﹤0.01% 2225
2020
Q1 		$2.77M Sell
60,147
-49,640
-45% -$2.49M ﹤0.01% 2126
2019
Q4 		$6.6M Sell
109,787
-3,921
-3% -$234K ﹤0.01% 1881
2019
Q3 		$6.43M Buy
113,708
+1,762
+2% +$99.1K ﹤0.01% 1839
2019
Q2 		$6.23M Buy
111,946
+14,111
+14% +$736K ﹤0.01% 1867
2019
Q1 		$4.94M Buy
97,835
+19,403
+25% +$863K ﹤0.01% 1986
2018
Q4 		$3.16M Sell
78,432
-5,237
-6% -$270K ﹤0.01% 2140
2018
Q3 		$5.8M Buy
83,669
+35,569
+74% +$2.7M ﹤0.01% 1965
2018
Q2 		$3.64M Sell
48,100
-39,025
-45% -$2.46M ﹤0.01% 2158
2018
Q1 		$4.59M Buy
87,125
+20,031
+30% +$1.16M ﹤0.01% 1993
2017
Q4 		$3.58M Buy
67,094
+6,378
+11% +$355K ﹤0.01% 2080
2017
Q3 		$3.62M Buy
60,716
+23,663
+64% +$1.43M ﹤0.01% 2051
2017
Q2 		$2.92M Buy
37,053
+737
+2% +$60.3K ﹤0.01% 2090
2017
Q1 		$3.01M Buy
36,316
+1,875
+5% +$139K ﹤0.01% 2021
2016
Q4 		$2.73M Sell
34,441
-277
-0.8% -$20.1K ﹤0.01% 2041
2016
Q3 		$2.43M Buy
34,718
+4,076
+13% +$226K ﹤0.01% 2044
2016
Q2 		$1.19M Buy
30,642
+510
+2% +$21.2K ﹤0.01% 2293
2016
Q1 		$1.22M Buy
30,132
+3,077
+11% +$195K ﹤0.01% 2259
2015
Q4 		$2.4M Buy
27,055
+804
+3% +$63.5K ﹤0.01% 1990
2015
Q3 		$1.94M Buy
26,251
+13,827
+111% +$1.15M ﹤0.01% 2080
2015
Q2 		$1M Buy
+12,424
New +$809K ﹤0.01% 2415

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab's EGRX Position: Q3 2024 in Review

Charles Schwab sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 50,589 shares — an estimated $283K sold.

Charles Schwab first reported a position in EGRX in Q2 2015 and held it in 37 quarters. The position peaked at $6.6M in Q4 2019. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • Charles Schwab reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 50,589 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $283K.
  • Charles Schwab first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 37 quarters.
  • Charles Schwab's Eagle Pharmaceuticals, Inc. position peaked at $6.6M in Q4 2019.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.